After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

The European Commission is likely to act rapidly on the formal approval of coronavirus treatments casirivimab/imdevimab and regdanvimab.

While Lilly's antibody combination of etesevimab and bamlanivimab is still going strong in the US, the company has lost out to Roche's Ronapreve in the EU.

Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.